NCT03239145View on ClinicalTrials.gov

Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor

PHASE1CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

August 31, 2017

Primary Completion Date

December 13, 2024

Study Completion Date

December 13, 2024

Conditions
Advanced Solid Tumor
Interventions
DRUG

Pembrolizumab

Pembrolizumab is designed to augment the natural ability of the immune system to recognize and target cancer cells

DRUG

Trebananib

AMG386 is a drug that may kill tumor cells and blocks blood vessels that supply the tumor with nutrients and oxygen

Trial Locations (2)

02215

Beth Israel Deaconess Medical Center, Boston

Dana Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Amgen
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Amgen

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT03239145 - Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor | Biotech Hunter | Biotech Hunter